This study is in progress, not accepting new patients

Predictive Biomarkers For Pediatric Chronic Graft-Versus-Host Disease

a study on Graft Versus Host Disease Bronchiolitis Obliterans

Eligibility: for people ages up to 18 years (full criteria)
Healthy Volunteers: healthy people welcome
Location: at UCSF
Dates: study started November 2013
completion around December 2025

Description

Summary

Chronic graft-versus-host disease (cGVHD) can be hard to diagnose, difficult to manage and contributes significantly to morbidity and mortality in hematopoietic stem cell transplantation patients.

The research will look into identifying and validating cGVHD biological indicators (=bio-markers) which will be evaluated whether they can predict a future development of the disease.

The study hypothesis is that a number of previously reported cGVHD bio-markers, known to be present at the time of cGVHD diagnosis, will also be present at earlier time points, before cGVHD develops.

Following validation, the bio-markers will be beneficial for finding those patients who are in higher risk to develop cGVHD.

By identifying the higher-risk group, which is more likely to develop cGVHD, a pre-emptive therapy might be applied in order to prevent or reduce the prevalence of the disease.

Official Title

Applying Biomarkers to Long-term Effects in Child and Adolescent Cancer Treatment (ABLE Team) - Predictive Biomarkers For Pediatric Chronic Graft-Versus-Host Disease

Keywords

Chronic Graft vs Host Disease, Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

Eligibility

You can join if…

Open to people ages up to 18 years

Allogeneic hematopoietic stem cell transplantation for any malignant or non-malignant disease.
Age 0-17.99 years at the time of transplantation.
Bone marrow, peripheral blood stem cell and umbilical cord blood (including single or double cord blood) as the graft source.
Any conditioning regimen with any chemotherapy / radiation therapy combination. Haploidentical donor transplants with post-transplant cyclophosphamide are also allowed.
Use of serotherapy is permitted.
Any graft-versus-host disease prophylaxis is permitted, including post-HSCT cyclophosphamide.
If participant weighs between 0-20 kg, participant must be able to provide 15 ml of whole blood at each time point.
If participant weighs over 20 kg, participant must be able to provide 1ml/kg of whole blood, up to a maximum of 23 mL for the pre-conditioning sample and 32 mL for samples at day +100, 6-months, 12-months, +/- the cGVHD sample.
Written informed consent from parents.
Assent from study participant when appropriate.
Participation on other clinical trials is acceptable.

You CAN'T join if...

Autologous HSCT.
Patients referred to a Bone Marrow Transplant (BMT) center from a non-BMT center, where it is anticipated (at the discretion of the center PI) that adequate follow up according to the rules of this protocol can not be met, including the requirement for a reassessment by the BMT center at the time of cGVHD diagnosis.
Ex-vivo T-cell depletion of graft source (e.g. CD34 selection).
Second (or greater) allogeneic transplants (first allogeneic transplant where a previous autologous transplant was performed is permitted).
Syngeneic transplants.

Locations

UCSF Benioff Children's Hospital
San Francisco California 94143 United States
City of Hope National Medical Center
Duarte California 91010 United States

Details

Status: in progress, not accepting new patients
Start Date: November 2013
Completion Date: December 2025 (estimated)
Sponsor: University of British Columbia
ID: NCT02067832
Study Type: Observational
Participants: About 302 people participating
Last Updated: December 2023